INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
MILFORD, Mass., PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to ...
Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot
* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000 * Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are ...
We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other medical AI ...
* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 * Strongbridge Biopharma Plc - on schedule to commence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results